Bristol Myers Squibb (BMY) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bristol myers Squibb Company  (NYSE: BMY)

Bristol Myers Squibb's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bristol Myers Squibb in the second quarter 2026?
Bristol myers Squibb Company achieved a return on average equity (ROE) of 46.65 % in its second quarter 2026, this is above BMY's average return on equity of 20.03%.
Bristol Myers Squibb Companys equity during the 12 months ending in the second quarter 2026 are valued at $19 billion

ROE has advanced compared to 38.94% in the first quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 19 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 265, from total ROE ranking in the first quarter 2026 at 270.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 27.62 % 15.21 % 12.92 % 8.14 % -
Y / Y Net Income Change 152.55 % 8.77 % 1327.63 % 80.66 % -22.03 %
Net Income (TTM) in Millions 9,274 7,271 7,055 6,046 5,066
Return On Equity (TTM) 46.65 % 38.94 % 39.17 % 34.59 % 29.57 %
BMY's Total Ranking # 265 # 270 # 207 # 270 # 312
Equity (TTM) in Millions 22,319 20,102 18,506 18,600 17,489
Seq. Equity Change 11.03 % 8.62 % -0.51 % 6.35 % 0.23 %
Seq. Net Income Change 23.82 % 146.82 % -50.57 % 67.17 % -46.67 %

Back to BMY Management Effectiveness >> BMY's 5 Years Annual ROE >> Compare BMY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 20
Sector # 41
Overall # 265

Return On Equity Statistics
High Average Low
74.74 %
20.03 %
-53.17 %
(Dec. 31, 2009)   (Dec 31 2024)



  News about Bristol myers Squibb Company Return on Equity ROE

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-gener...

BioNTech and Bristol Myers Squibb Forge Strategic Alliance for Bispecific Antibody Development Amid Competitive Market Pressures MAINZ, Germany, and PRINCETON, USA June 2, 2025 In a significant move that underscores the dynamic landscape of oncology therapeutics, BioNTech (Nasdaq: BNTX) and Bristol Myers Squibb (NYSE: BMY) have announced a global strategic partnership aimed at co-developing and co-commercializing BioNTech s investigational bispecific antibody candidate, BNT327. This collaboration seeks to enhance the therapeutic options available for patients suffering from a range of solid tumor types.BNT327 represents a critical advancement in targeted therapies, utilizing bispecific antibody technology to engage two distinct targets simultaneously, thereby improving the precision and efficacy of cancer treatment. This innovative approach has the potential to revolutionize the current treatment paradigms for various malignancies, tapping into the promise of personalized medicine that is increasingly becoming a standard expectation in cancer care.



BMY Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 18,506 16,388 29,485 31,118 36,006
Y / Y Equity Change 12.92 % -44.42 % -5.25 % -13.58 % -4.95 %
Net Income in Millions 7,055 -8,933 8,040 6,345 7,014
Y / Y Net Income Change - - 26.71 % -9.54 % -
Return On Equity 38.12 % -54.51 % 27.27 % 20.39 % 19.48 %

Back to BMY Management Effectiveness >> BMY's 5 Years Annual ROE >> Compare BMY ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 38.12 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BMY's' Return on Equity at Yahoo Finance
BMY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BMY's Competitors
Subscribers only: Roe for Bristol Myers Squibb's Suppliers
Subscribers only: Return On Equity for BMY's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Pulmatrix Inc   108.83 %
Arbutus Biopharma Corp  106.04 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Amgen Inc   89.32 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %

Date modified: 2026-09-14T03:49:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.